![]()
|
|
||||||||
J. Biol. Chem., Vol. 279, Issue 47, 49099-49104, November 19, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reduces Amyloid
-Protein Levels and Amyloid Plaque Formation in the Brains of Transgenic Mice*



From the Department of Neuroscience and Section of Old Age Psychiatry, The Institute of Psychiatry, King's College London SE5 8AF, United Kingdom
Accumulation of cerebral amyloid
-protein (A
) is believed to be part of the pathogenic process in Alzheimer's disease. A
is derived by proteolytic cleavage from a precursor protein, the amyloid precursor protein (APP). APP is a type-1 membrane-spanning protein, and its carboxyl-terminal intracellular domain binds to X11
, a neuronal adaptor protein. X11
has been shown to inhibit the production of A
in transfected non-neuronal cells in culture. However, whether this is also the case in vivo in the brain and whether X11
can also inhibit the deposition of A
as amyloid plaques is not known. Here we show that transgenic overexpression of X11
in neurons leads to a decrease in cerebral A
levels in transgenic APPswe Tg2576 mice that are a model of the amyloid pathology of Alzheimer's disease. Moreover, overexpression of X11
retards amyloid plaque formation in these APPswe mice. Our findings suggest that modulation of X11
function may represent a novel therapeutic approach for preventing the amyloid pathology of Alzheimer's disease.
Received for publication, May 19, 2004 , and in revised form, September 1, 2004.
* This work was supported by grants from the Medical Research Council, Wellcome Trust, European Union Fifth Framework, Research into Aging, The Health Foundation, and the Alzheimer's Disease Society. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Both authors contributed equally to this work.
To whom correspondence should be addressed: Dept. of Neuroscience, P. O. Box P037, The Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK. Tel.: 44-207-8480393; Fax: 44-207-7080017; E-mail: chris.miller{at}iop.kcl.ac.uk.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
Y. Sano, A. Syuzo-Takabatake, T. Nakaya, Y. Saito, S. Tomita, S. Itohara, and T. Suzuki Enhanced Amyloidogenic Metabolism of the Amyloid beta-Protein Precursor in the X11L-deficient Mouse Brain J. Biol. Chem., December 8, 2006; 281(49): 37853 - 37860. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-S. Hoe, T. S. Tran, Y. Matsuoka, B. W. Howell, and G. W. Rebeck DAB1 and Reelin Effects on Amyloid Precursor Protein and ApoE Receptor 2 Trafficking and Processing J. Biol. Chem., November 17, 2006; 281(46): 35176 - 35185. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Suzuki, Y. Araki, T. Yamamoto, and T. Nakaya Trafficking of Alzheimer's Disease-Related Membrane Proteins and Its Participation in Disease Pathogenesis J. Biochem., June 1, 2006; 139(6): 949 - 955. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Neumann, S. Schobel, S. Jager, A. Trautwein, C. Haass, C. U. Pietrzik, and S. F. Lichtenthaler Amyloid Precursor-like Protein 1 Influences Endocytosis and Proteolytic Processing of the Amyloid Precursor Protein J. Biol. Chem., March 17, 2006; 281(11): 7583 - 7594. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Tudor, M. S. Perkinton, A. Schmidt, S. Ackerley, J. Brownlees, N. J. O. Jacobsen, H. L. Byers, M. Ward, A. Hall, P. N. Leigh, et al. ALS2/Alsin Regulates Rac-PAK Signaling and Neurite Outgrowth J. Biol. Chem., October 14, 2005; 280(41): 34735 - 34740. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |